专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060235031A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors 有权
标题翻译： 6,6-双环取代杂双环蛋白激酶抑制剂
公开(公告)号：US20060235031A1
公开(公告)日：2006-10-19
申请号：US11095162
申请日：2005-03-31
申请人： Lee Arnold , Heather Coate , Andrew Crew , Hanqing Dong , Kenneth Foreman , Ayako Honda , Radoslaw Laufer , An-Hu Li , Kristen Mulvihill , Mark Mulvihill , Anthony Nigro , Bijoy Panicker , Arno Steinig , Qingua Weng , Douglas Werner , Michael Wyle , Tao Zhang , Cara Cesario , Yingchuan Sun
发明人： Lee Arnold , Heather Coate , Andrew Crew , Hanqing Dong , Kenneth Foreman , Ayako Honda , Radoslaw Laufer , An-Hu Li , Kristen Mulvihill , Mark Mulvihill , Anthony Nigro , Bijoy Panicker , Arno Steinig , Qingua Weng , Douglas Werner , Michael Wyle , Tao Zhang , Cara Cesario , Yingchuan Sun
IPC分类号： A61K31/52
CPC分类号： C07F5/025 , C07D471/04 , C07D487/04
摘要： Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
摘要翻译：下式的化合物及其药学上可接受的盐，其中X 1，X 2，X 3，X 4， X 5，X 6，X 7，R 1和Q 1 在本文中定义，抑制IGF-1R酶，并且可用于治疗和/或预防过度增殖性疾病如癌症，炎症，牛皮癣，过敏/哮喘，免疫系统的疾病和状况，中枢的疾病和状况神经系统。

2. 发明申请

US20060084654A1 Imidazopyrazine tyrosine kinase inhibitors 有权
标题翻译：咪唑吡嗪酪氨酸激酶抑制剂
公开(公告)号：US20060084654A1
公开(公告)日：2006-04-20
申请号：US10965182
申请日：2004-10-14
申请人： Patricia Beck , Cara Cesario , Matthew Cox , Han-Qing Dong , Kenneth Foreman , Mark Mulvihill , Anthony Nigro , Lydia Saroglou , Arno Steinig , Yingchuan Sun , Qinghua Weng , Douglas Werner , Robin Wilkes , Jonathan Williams
发明人： Patricia Beck , Cara Cesario , Matthew Cox , Han-Qing Dong , Kenneth Foreman , Mark Mulvihill , Anthony Nigro , Lydia Saroglou , Arno Steinig , Yingchuan Sun , Qinghua Weng , Douglas Werner , Robin Wilkes , Jonathan Williams
IPC分类号： A61K31/498 , C07D487/04
CPC分类号： C07D487/04
摘要： Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
摘要翻译：式I化合物及其药学上可接受的盐，其中Q 1和R 1在本文中定义，抑制IGF-1R酶，并且可用于治疗和/或预防通过抑制酪氨酸激酶对治疗作出反应的各种疾病和病症。

3. 发明申请

US20080227788A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS 有权
标题翻译：咪唑吡嗪类激酶激酶抑制剂
公开(公告)号：US20080227788A9
公开(公告)日：2008-09-18
申请号：US10965182
申请日：2004-10-14
申请人： Patricia Beck , Cara Cesario , Matthew Cox , Han-Qing Dong , Kenneth Foreman , Mark Mulvihill , Anthony Nigro , Lydia Saroglou , Arno Steinig , Yingchuan Sun , Qinghua Weng , Douglas Werner , Robin Wilkes , Jonathan Williams
发明人： Patricia Beck , Cara Cesario , Matthew Cox , Han-Qing Dong , Kenneth Foreman , Mark Mulvihill , Anthony Nigro , Lydia Saroglou , Arno Steinig , Yingchuan Sun , Qinghua Weng , Douglas Werner , Robin Wilkes , Jonathan Williams
IPC分类号： A61K31/498 , C07D487/04
CPC分类号： C07D487/04
摘要： Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
摘要翻译：式I化合物及其药学上可接受的盐，其中Q 1和R 1在本文中定义，抑制IGF-1R酶，并且可用于治疗和/或预防通过抑制酪氨酸激酶对治疗作出反应的各种疾病和病症。

4. 发明申请

US20070129364A1 Pyrrolopyridine kinase inhibiting compounds 审中-公开
标题翻译：吡咯并吡啶激酶抑制化合物
公开(公告)号：US20070129364A1
公开(公告)日：2007-06-07
申请号：US11634003
申请日：2006-12-05
申请人： Han-Qing Dong , Kenneth Foreman , An-Hu Li , Mark Mulvihill , Bijoy Panicker , Arno Steinig , Kathryn Stolz , Qinghua Weng , Meizhong Jin , Brian Volk , Jing Wang , Ti Wang , James Beard
发明人： Han-Qing Dong , Kenneth Foreman , An-Hu Li , Mark Mulvihill , Bijoy Panicker , Arno Steinig , Kathryn Stolz , Qinghua Weng , Meizhong Jin , Brian Volk , Jing Wang , Ti Wang , James Beard
IPC分类号： A61K31/5377 , A61K31/496 , A61K31/4745 , C07D471/02
CPC分类号： C07D471/04
摘要： Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least one of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3β, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Met, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
摘要翻译：由式（I）表示的化合物或其立体异构体或其药学上可接受的盐是Abl，Aurora-A，Blk，c-Raf，cSRC，Src，PRK2，FGFR3，Flt3，Lck，Mek1，PDK中的至少一种的抑制剂 -1，GSK3beta，EGFR，p70S6K，BMX，SGK，CaMKII，Tie-2，IGF-1R，Ron，Met和KDR激酶，用于治疗和/或预防各种疾病和病症，癌症。

5. 发明申请

US20070032512A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors 失效
标题翻译： 6,6-双环取代的含硫杂环二环蛋白激酶抑制剂
公开(公告)号：US20070032512A1
公开(公告)日：2007-02-08
申请号：US11498975
申请日：2006-08-03
申请人： Qun-Sheng Ji , Mark Mulvihill , Arno Steinig , Qinghua Weng
发明人： Qun-Sheng Ji , Mark Mulvihill , Arno Steinig , Qinghua Weng
IPC分类号： A61K31/519 , C07D498/02 , A61K31/4743
CPC分类号： C07D495/04
摘要： Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
摘要翻译：下式的化合物及其药学上可接受的盐，其中X 1，X 2，X 3和Q 1 在本文中定义，抑制IGF-1R酶，并且可用于治疗和/或预防过度增殖性疾病如癌症，炎症，牛皮癣，过敏/哮喘，免疫系统的疾病和状况，中枢的疾病和状况神经系统。

6. 发明授权

US06916804B2 Pyrimidine A2b selective antagonist compounds, their synthesis and use 失效
标题翻译：嘧啶A2b选择性拮抗剂化合物，其合成和用途
公开(公告)号：US06916804B2
公开(公告)日：2005-07-12
申请号：US10326204
申请日：2002-12-20
申请人： Arlindo Castelhano , Bryan McKibben , Arno Steinig , Eric Collington
发明人： Arlindo Castelhano , Bryan McKibben , Arno Steinig , Eric Collington
IPC分类号： C07D243/08 , A61K31/506 , A61K31/513 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K31/551 , A61P1/00 , A61P1/12 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/06 , A61P17/00 , A61P17/04 , A61P19/02 , A61P27/02 , A61P35/00 , A61P37/08 , A61P43/00 , C07D239/42 , C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D411/12 , C07D413/12 , C07D417/12 , C07D471/10 , C07D487/04 , C07D239/02 , A61K31/505 , A61K31/535 , C07D413/00
CPC分类号： C07D239/48 , C07D401/12 , C07D403/12
摘要： The subject invention provides compounds having the structure: wherein R1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R2 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety; R3 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R2 and R3 are joined to form a heterocyclic ring; wherein the dashed line represents a second bond which may be present or absent, and when present R3 is oxygen; R4 and R5 are each independently substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R4NR5 together form a substituted or unsubstituted monocyclic or bicyclic, heterocyclic or heteroaryl moiety containing from 1 to 6 heteroatoms; R12 is hydrogen, alkyl, halogen or cyano; and n is 0, 1, 2, 3 or 4, or an enantiomer, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating a disease associated with the A2b adenosine receptor by administering a therapeutically effective amount of the compounds of the invention.
摘要翻译：本发明提供具有以下结构的化合物：其中R 1是取代或未取代的苯基或含有1至5个杂原子的5-6元杂环或杂芳族环; R 2是氢或取代或未取代的烷基，-C（O） - 烷基，-C（O）-O-烷基，烷氧基，环烷基，烯基，单环或双环芳基，杂芳基或杂环部分; R 3是氢或取代或未取代的烷基，-C（O） - 烷基，-C（O）-O-烷基，烷氧基，环烷基，烯基，单环或双环芳基，杂芳基或杂环部分或R 2和R 3 3连接形成杂环; 其中虚线表示可以存在或不存在的第二键，并且当存在时R 3为氧; R 4和R 5各自独立地是取代或未取代的烷基，-C（O） - 烷基，-C（O）-O-烷基，烷氧基，环烷基，烯基，单环或双环芳基，杂芳基或杂环部分或R 4 NR 5一起形成含有1至6个杂原子的取代或未取代的单环或双环，杂环或杂芳基部分 ; R 12是氢，烷基，卤素或氰基; 和n为0,1,2,3或4，或其对映异构体或特定的互变异构体或其药学上可接受的盐，以及通过以下方式治疗与Aβ2-2腺苷受体相关的疾病的方法：施用治疗有效量的本发明化合物。

7. 发明申请

US20050119271A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use 失效
标题翻译：嘧啶A2B选择性拮抗剂化合物，其合成和用途
公开(公告)号：US20050119271A1
公开(公告)日：2005-06-02
申请号：US10992239
申请日：2004-11-18
申请人： Arlindo Castelhano , Bryan McKibben , Arno Steinig , Eric Collington
发明人： Arlindo Castelhano , Bryan McKibben , Arno Steinig , Eric Collington
IPC分类号： C07D243/08 , A61K31/506 , A61K31/513 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K31/551 , A61P1/00 , A61P1/12 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/06 , A61P17/00 , A61P17/04 , A61P19/02 , A61P27/02 , A61P35/00 , A61P37/08 , A61P43/00 , C07D239/42 , C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D411/12 , C07D413/12 , C07D417/12 , C07D471/10 , C07D487/04 , C07D43/02
CPC分类号： C07D239/48 , C07D401/12 , C07D403/12
摘要： The subject invention provides compounds having the structure: wherein R1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R2 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)-O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety; R3 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)-O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R2 and R3 are joined to form a heterocyclic ring; wherein the dashed line represents a second bond which may be present or absent, and when present R3 is oxygen; R4 and R5 are each independently substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)-O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R4NR5 together form a substituted or unsubstituted monocyclic or bicyclic, heterocyclic or heteroaryl moiety containing from 1 to 6 heteroatoms; R12 is hydrogen, alkyl, halogen or cyano; and n is 0, 1, 2, 3 or 4, or an enantiomer, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating a disease associated with the A2b adenosine receptor by administering a therapeutically effective amount of the compounds of the invention.
摘要翻译：本发明提供具有以下结构的化合物：其中R 1是取代或未取代的苯基或含有1至5个杂原子的5-6元杂环或杂芳族环; R 2是氢或取代或未取代的烷基，-C（O） - 烷基，-C（O）-O-烷基，烷氧基，环烷基，烯基，单环或双环芳基，杂芳基或杂环部分; R 3是氢或取代或未取代的烷基，-C（O） - 烷基，-C（O）-O-烷基，烷氧基，环烷基，烯基，单环或双环芳基，杂芳基或杂环部分或R 2和R 3 3连接形成杂环; 其中虚线表示可以存在或不存在的第二键，并且当存在时R 3为氧; R 4和R 5各自独立地是取代或未取代的烷基，-C（O） - 烷基，-C（O）-O-烷基，烷氧基，环烷基，烯基，单环或双环芳基，杂芳基或杂环部分或R 4 NR 5一起形成含有1至6个杂原子的取代或未取代的单环或双环，杂环或杂芳基部分 ; R 12是氢，烷基，卤素或氰基; 和n为0,1,2,3或4，或其对映异构体或特定的互变异构体或其药学上可接受的盐，以及通过以下方式治疗与Aβ2-2腺苷受体相关的疾病的方法：施用治疗有效量的本发明化合物。

8. 发明授权

US07501407B2 Pyrimidine A2B selective antagonist compounds, their synthesis and use 失效
标题翻译：嘧啶A2B选择性拮抗剂化合物，其合成和用途
公开(公告)号：US07501407B2
公开(公告)日：2009-03-10
申请号：US10992239
申请日：2004-11-18
申请人： Arlindo Castelhano , Bryan McKibben , Arno Steinig , Eric Collington
发明人： Arlindo Castelhano , Bryan McKibben , Arno Steinig , Eric Collington
IPC分类号： C07D403/12 , C07D403/14 , A61K31/505
CPC分类号： C07D239/48 , C07D401/12 , C07D403/12
摘要： The subject invention provides compounds having the structure: wherein R1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R2 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety; R3 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R2 and R3 are joined to form a heterocyclic ring; wherein the dashed line represents a second bond which may be present or absent, and when present R3 is oxygen; R4 and R5 are each independently substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R4NR5 together form a substituted or unsubstituted monocyclic or bicyclic, heterocyclic or heteroaryl moiety containing from 1 to 6 heteroatoms; R12 is hydrogen, alkyl, halogen or cyano; and n is 0, 1, 2, 3 or 4, or an enantiomer, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating a disease associated with the A2b adenosine receptor by administering a therapeutically effective amount of the compounds of the invention.
摘要翻译：本发明提供具有以下结构的化合物：其中R 1是取代或未取代的苯基或含有1至5个杂原子的5-6元杂环或杂芳族环; R 2是氢或取代或未取代的烷基，-C（O） - 烷基，-C（O）-O-烷基，烷氧基，环烷基，烯基，单环或双环芳基，杂芳基或杂环部分; R 3是氢或取代或未取代的烷基，-C（O） - 烷基，-C（O）-O-烷基，烷氧基，环烷基，烯基，单环或双环芳基，杂芳基或杂环部分，或R 2和R 3是连接形成杂环; 其中虚线表示可以存在或不存在的第二键，并且当存在时，R3是氧; R 4和R 5各自独立地是取代或未取代的烷基，-C（O） - 烷基，-C（O）-O-烷基，烷氧基，环烷基，链烯基，单环或双环芳基，杂芳基或杂环部分或R4NR5一起形成含有1至6个杂原子的取代或未取代的单环或双环，杂环或杂芳基部分; R 12是氢，烷基，卤素或氰基; 和n为0,1,2,3或4或其对映异构体或其特异性互变异构体或其药学上可接受的盐，以及通过施用治疗有效量的化合物治疗与A2b腺苷受体相关的疾病的方法的本发明。

9. 发明授权

US07645754B2 Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use 失效
公开(公告)号：US07645754B2
公开(公告)日：2010-01-12
申请号：US10536119
申请日：2007-06-19
申请人： Arlindo Castelhano , Bryan McKibben , Arno Steinig
发明人： Arlindo Castelhano , Bryan McKibben , Arno Steinig
IPC分类号： C07D487/04 , A61K31/519 , A61P11/06
CPC分类号： C07D487/04
摘要： The subject invention provides compounds having the structure: wherein, R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O) Ra; R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra, or R1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(═O)OH; R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb; R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl; R5 is —(CH2)mOR6, —CHNOR7, —C(═O)NR8R9, —(CH2)mC(═O)OR10, —(CH2)kC(═O)NR11R12; wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring; R7 is hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl; R8 and R9 are each independently hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl, (C1-C30)alkylamino, (C1-C30)alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, or R8, N, and R9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring; R10 is hydrogen or a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or heterocyclic ring; R11, N and R12 together form a 4-8 membered heterocyclic ring; Ra and Rb are each independently hydrogen or alkyl; m is 0, 1, 2 or 3; and k is 1, 2 or 3, or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.

10. 发明申请

US20080261943A1 PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE 失效
公开(公告)号：US20080261943A1
公开(公告)日：2008-10-23
申请号：US10536119
申请日：2007-06-19
申请人： Arlindo Castelhano , Bryan McKibben , Arno Steinig
发明人： Arlindo Castelhano , Bryan McKibben , Arno Steinig
IPC分类号： A61K31/519 , C07D487/04
CPC分类号： C07D487/04
摘要： The subject invention provides compounds having the structure: wherein, R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NH C(═O) Ra; R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra, or R1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(═O)OH; R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb; R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl; R5 is —(CH2)mOR6, —CHNOR7, —C(═O)NR8R9, —(CH2)mC(═O)OR10, —(CH2)kC(═O)NR11R12; wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring; R7 is hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl; R8 and R9 are each independently hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl, (C1-C30)alkylamino, (C1-C30)alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, or R8, N, and R9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring; R10 is hydrogen or a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or heterocyclic ring; R11, N and R12 together form a 4-8 membered heterocyclic ring; Ra and Rb are each independently hydrogen or alkyl; m is 0, 1, 2 or 3; and k is 1, 2 or 3, or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式